vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and PROSPERITY BANCSHARES INC (PB). Click either name above to swap in a different company.
PROSPERITY BANCSHARES INC is the larger business by last-quarter revenue ($367.6M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). PROSPERITY BANCSHARES INC runs the higher net margin — 31.6% vs 11.1%, a 20.5% gap on every dollar of revenue. Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 19.2%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Prosperity Bancshares, Inc. is a bank holding company headquartered in Houston, Texas with operations in Texas and central Oklahoma. As of December 31, 2019, the company operated 285 branches: 65 in the Houston area, including The Woodlands, Texas; 30 in South Texas, including Corpus Christi, Texas and Victoria, Texas; 75 in the Dallas–Fort Worth metroplex; 22 in East Texas; 29 in Central Texas, including Austin, Texas and San Antonio; 34 in West Texas, including Lubbock, Texas, Midland–Odess...
ANIP vs PB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $367.6M |
| Net Profit | $27.5M | $116.3M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | — |
| Net Margin | 11.1% | 31.6% |
| Revenue YoY | 29.6% | — |
| Net Profit YoY | 367.5% | -10.7% |
| EPS (diluted) | $1.14 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $367.6M | ||
| Q4 25 | $247.1M | $275.0M | ||
| Q3 25 | $227.8M | $273.4M | ||
| Q2 25 | $211.4M | $267.7M | ||
| Q1 25 | $197.1M | $265.4M | ||
| Q4 24 | $190.6M | $267.8M | ||
| Q3 24 | $148.3M | $261.7M | ||
| Q2 24 | $138.0M | $258.8M |
| Q1 26 | — | $116.3M | ||
| Q4 25 | $27.5M | $139.9M | ||
| Q3 25 | $26.6M | $137.6M | ||
| Q2 25 | $8.5M | $135.2M | ||
| Q1 25 | $15.7M | $130.2M | ||
| Q4 24 | $-10.3M | $130.1M | ||
| Q3 24 | $-24.2M | $127.3M | ||
| Q2 24 | $-2.3M | $111.6M |
| Q1 26 | — | — | ||
| Q4 25 | 14.1% | 65.1% | ||
| Q3 25 | 15.9% | 64.4% | ||
| Q2 25 | 6.6% | 64.3% | ||
| Q1 25 | 13.3% | 62.7% | ||
| Q4 24 | -2.3% | 62.0% | ||
| Q3 24 | -13.8% | 62.1% | ||
| Q2 24 | 3.7% | 55.2% |
| Q1 26 | — | 31.6% | ||
| Q4 25 | 11.1% | 50.9% | ||
| Q3 25 | 11.7% | 50.3% | ||
| Q2 25 | 4.0% | 50.5% | ||
| Q1 25 | 8.0% | 49.1% | ||
| Q4 24 | -5.4% | 48.6% | ||
| Q3 24 | -16.3% | 48.6% | ||
| Q2 24 | -1.7% | 43.1% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $1.14 | $1.48 | ||
| Q3 25 | $1.13 | $1.45 | ||
| Q2 25 | $0.36 | $1.42 | ||
| Q1 25 | $0.69 | $1.37 | ||
| Q4 24 | $-0.45 | $1.36 | ||
| Q3 24 | $-1.27 | $1.34 | ||
| Q2 24 | $-0.14 | $1.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $8.2B |
| Total Assets | $1.4B | $43.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — |
| Q1 26 | — | $8.2B | ||
| Q4 25 | $540.7M | $7.6B | ||
| Q3 25 | $505.8M | $7.7B | ||
| Q2 25 | $436.8M | $7.6B | ||
| Q1 25 | $418.6M | $7.5B | ||
| Q4 24 | $403.7M | $7.4B | ||
| Q3 24 | $405.9M | $7.4B | ||
| Q2 24 | $455.8M | $7.3B |
| Q1 26 | — | $43.6B | ||
| Q4 25 | $1.4B | $38.5B | ||
| Q3 25 | $1.4B | $38.3B | ||
| Q2 25 | $1.3B | $38.4B | ||
| Q1 25 | $1.3B | $38.8B | ||
| Q4 24 | $1.3B | $39.6B | ||
| Q3 24 | $1.3B | $40.1B | ||
| Q2 24 | $920.8M | $39.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | — |
| Free Cash FlowOCF − Capex | $29.1M | — |
| FCF MarginFCF / Revenue | 11.8% | — |
| Capex IntensityCapex / Revenue | 0.5% | — |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $30.4M | $78.3M | ||
| Q3 25 | $44.1M | $194.8M | ||
| Q2 25 | $75.8M | $98.2M | ||
| Q1 25 | $35.0M | $178.2M | ||
| Q4 24 | $15.9M | $-205.8M | ||
| Q3 24 | $12.5M | $274.6M | ||
| Q2 24 | $17.4M | $216.5M |
| Q1 26 | — | — | ||
| Q4 25 | $29.1M | $68.5M | ||
| Q3 25 | $38.0M | $185.7M | ||
| Q2 25 | $71.8M | $91.8M | ||
| Q1 25 | $32.5M | $171.1M | ||
| Q4 24 | $13.5M | $-210.7M | ||
| Q3 24 | $7.7M | $270.2M | ||
| Q2 24 | $13.0M | $211.8M |
| Q1 26 | — | — | ||
| Q4 25 | 11.8% | 24.9% | ||
| Q3 25 | 16.7% | 67.9% | ||
| Q2 25 | 34.0% | 34.3% | ||
| Q1 25 | 16.5% | 64.5% | ||
| Q4 24 | 7.1% | -78.7% | ||
| Q3 24 | 5.2% | 103.3% | ||
| Q2 24 | 9.4% | 81.8% |
| Q1 26 | — | — | ||
| Q4 25 | 0.5% | 3.6% | ||
| Q3 25 | 2.7% | 3.3% | ||
| Q2 25 | 1.9% | 2.4% | ||
| Q1 25 | 1.3% | 2.7% | ||
| Q4 24 | 1.3% | 1.8% | ||
| Q3 24 | 3.2% | 1.7% | ||
| Q2 24 | 3.2% | 1.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 0.56× | ||
| Q3 25 | 1.66× | 1.42× | ||
| Q2 25 | 8.87× | 0.73× | ||
| Q1 25 | 2.23× | 1.37× | ||
| Q4 24 | — | -1.58× | ||
| Q3 24 | — | 2.16× | ||
| Q2 24 | — | 1.94× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PB
| Net Interest Income | $321.1M | 87% |
| Noninterest Income | $46.5M | 13% |
